Tyra Biosciences Inc (TYRA) Actualités

Form ARS - Annual Report to Security Holders

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights

Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights PR...

Tyra Biosciences to Present at Upcoming Investor Conferences

Tyra Biosciences to Present at Upcoming Investor Conferences PR Newswire CARLSBAD, Calif., Feb. 11, 2025...

Form 144 - Report of proposed sale of securities

Form 8-K - Current report

Tyra Biosciences Announces Appointment of Adele Gulfo to Board of Directors

Tyra Biosciences Announces Appointment of Adele Gulfo to Board of Directors PR Newswire CARLSBAD, Calif., Jan...

Form 144 - Report of proposed sale of securities

Tyra Biosciences Announces Poster Presentations at 2025 ASCO Gastrointestinal Cancers Symposium

Tyra Biosciences Announces Poster Presentations at 2025 ASCO Gastrointestinal Cancers Symposium PR...

Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)

Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle...

Form 144 - Report of proposed sale of securities

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]